Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded up 1.7% during trading on Wednesday . The company traded as high as $29.09 and last traded at $29.0220. 39,035,343 shares traded hands during trading, a decline of 7% from the average daily volume of 41,787,016 shares. The stock had previously closed at $28.55.
Pfizer News Roundup
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Litigation overhang diminished: Pfizer reached a confidential settlement covering more than 6,000 federal Depo-Provera lawsuits involving alleged intracranial meningioma risk. Although the financial terms were not disclosed and Pfizer admitted no liability, the agreement removes uncertainty surrounding a sizable product-liability dispute. Pfizer Reaches Confidential Settlement in Depo-Provera Litigation
- Positive Sentiment: Results and growth drivers are supporting sentiment: Recent coverage points to Pfizer’s second-quarter performance exceeding analyst expectations, with vaccine and oncology products helping the outlook. The company previously reported quarterly revenue of $15.03 billion and adjusted earnings of $0.77 per share, above consensus estimates, while maintaining fiscal 2026 earnings guidance of $2.80–$3.00 per share. Pfizer Stock Reaches 52-Week Peak Following Results and Settlement
- Positive Sentiment: Pipeline expansion: Pfizer’s asthma candidate PF-08103402 has entered a Phase 1 clinical study. Early-stage testing does not establish efficacy, but the program adds another potential long-term growth opportunity to Pfizer’s development pipeline. Pfizer’s New Asthma Candidate Enters Phase 1
- Neutral Sentiment: Valuation debate: An analysis of whether investors should buy Pfizer below $30 argues that patient shareholders could be rewarded over the long term, but the stock’s recent rally means expectations and execution remain important. Should You Buy Pfizer Stock Below $30?
- Negative Sentiment: Options activity signals caution: Traders purchased approximately 147,173 put options, about 24% above typical daily put volume. This may indicate hedging or bearish positioning, although options activity alone does not determine Pfizer’s direction.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on PFE. JPMorgan Chase & Co. decreased their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Wolfe Research reiterated an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. BMO Capital Markets reduced their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and dropped their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $28.28.
Pfizer Trading Up 1.7%
The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $165.42 billion, a P/E ratio of 38.19 and a beta of 0.34. The business’s fifty day simple moving average is $25.69 and its two-hundred day simple moving average is $26.31.
Pfizer (NYSE:PFE – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the previous year, the firm posted $0.78 EPS. The business’s revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.
Pfizer Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 5.9%. The ex-dividend date was Friday, July 24th. Pfizer’s dividend payout ratio is 226.32%.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. Evolution Wealth Management Inc. lifted its holdings in Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 566 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth $26,000. Keb Asset Management LLC bought a new stake in Pfizer in the second quarter valued at about $26,000. HFM Investment Advisors LLC lifted its stake in Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares during the period. Finally, Field & Main Bank acquired a new stake in shares of Pfizer in the 2nd quarter valued at approximately $27,000. 68.36% of the stock is owned by institutional investors.
Pfizer Company Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Stories
- Five stocks we like better than Pfizer
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
